Tokai Pharmaceuticals Announces Updated Phase 2 Data on Galeterone In Patients with Advanced Prostate Cancer To Be Presented At The ESMO 2014 Congress

Tokai Pharmaceuticals, Inc.

, a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that updated, interim results from the company's ongoing Phase 2 clinical trial, ARMOR2, of its lead drug candidate, galeterone, in patients with castration resistant prostate cancer (CRPC) will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress, September 26-30, in Madrid, Spain. The presentation entitled “Galeterone in 4 patient populations of men with CRPC: Results from ARMOR2” will be presented by Mary-Ellen Taplin, M.D., associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School, and co-principal investigator of ARMOR2, as an oral presentation on Monday, September 29, 2014 from 2:00 to 3:45pm (CEST).